Non-small Cell Lung Cancer with Egfr Exon 20 Insertion
📧 Sign up to get email alerts when something new happens for Non-small Cell Lung Cancer with Egfr Exon 20 Insertion.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2025-12-17FDA Approved: RYBREVANT FASPRO — Original Application (Janssen Biotech, Inc.)
FDA approved Rybrevant FASPRO, a subcutaneous co-formulation of amivantamab and hyaluronidase-lpuj, under an original application by Janssen…